The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study

BACKGROUND: Niraparib is the only poly (adenosine diphosphate-ribose)-polymerase (PARP) inhibitor available as oral monotherapy for maintenance, regardless of BRCA mutational status. METHODS: This phase I, open-label, non-randomized, dose-escalation study was conducted in Japan using a 3 + 3 design....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Jpn J Clin Oncol
Hlavní autoři: Yonemori, Kan, Shimizu, Toshio, Kondo, Shunsuke, Iwasa, Satoru, Koyama, Takafumi, Kitano, Shigehisa, Sato, Jun, Shimomura, Akihiko, Shibaki, Ryota, Suri, Ajit, Kase, Yoichi, Sumino, Shuuji, Tamura, Kenji, Yamamoto, Noboru
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2021
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8086052/
https://ncbi.nlm.nih.gov/pubmed/33621324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyab013
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky